Comments on the three papers by the FDA/CDER research team on the regulatory perspective of the missing data problem.
This communication comments on the three papers by the FDA CDER research team on the regulatory perspective of the missing data problem. The focus is on two topics: causal estimand and sensitivity analysis. Copyright © 2016 John Wiley & Sons, Ltd.